Oruka Therapeutics, Inc.
A clinical-stage biotech developing longer-lasting antibody drugs for skin conditions like psoriasis, aiming for injections that may be needed only once or twice a year. Its lead candidates, ORKA-001 and ORKA-002, come from Paragon Therapeutics, a drug-discovery engine that also spawned other biotechs. The name blends Hebrew words for "skin" and "restoration," and the company went public in 2024 through a reverse merger with ARCA biopharma, trading as "ORKA."
Bought 1.00M · Sold 900.0K
Bought 122.9K
Granted 333.3K
Granted 435.0K
Bought 757.8K
Bought 634.7K
Granted 317.4K · Sold 140.0K
Sold 140.0K
Granted 76.7K · Sold 3.5K
Sold 405.6K
Sold 210.8K
Sold 199.8K
Granted 47.5K · Sold 24.2K
Granted 127.0K
Granted 109.2K · Sold 8.2K
Granted 100.0K
Granted 200.8K · Bought 50.0K · Sold 4.0K
Bought 83.1K
Granted 65.3K · Sold 5.0K
Granted 40.0K
Granted 81.5K · Sold 50.6K
Granted 62.3K · Sold 140.0K
Granted 65.8K
Granted 32.5K · Sold 1.5K
Granted 75.8K · Sold 75.8K
Granted 34.8K · Sold 22.1K
Sold 21.0K
Granted 1.07M · Bought 1.07M · Sold 26.0K
Bought 29.0K
Bought 11.0K
Sold 1.54M
Sold 1.46M
Sold 1.46M
Sold 1.46M
Sold 1.46M
Sold 1.46M
Sold 1.46M
Sold 1.46M
Sold 1.46M
Sold 1.46M
Sold 1.46M
Granted 25.0K · Sold 37.5K
Granted 23.4K · Sold 5.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Funicular Funds, LPReporting owner · 2 transactions | — | 7.74Mas of Jul 2022 | — | — | — |
| mccormack riley10% owner · 7 transactions | — | 4.42Mas of Jan 2015 | — | 1.00M | 900.0K |
| Koh Bong Y +6 co-filers10% owner · 5 transactions | — | 4.03Mas of Feb 2025 | — | 122.9K | — |
| Ma-Weaver Jacob +1 co-filerDirector · 1 transaction | — | 4.00Mas of Dec 2022 | — | — | — |
| Fairmount Funds Management LLC +4 co-filersDirector, 10% owner · 1 transaction | — | 3.71M | 333.3K | — | — |
| Fairmount Funds Management LLC +3 co-filersDirector, 10% owner · 2 transactions | — | 3.37Mas of Nov 2024 | 435.0K | — | — |
| Ma-Weaver Jacob +1 co-filerSee Footnote 1 · 26 transactions | — | 2.58Mas of May 2022 | — | 757.8K | — |
| Janus Henderson Group PLC +1 co-filer10% owner · 15 transactions | — | 2.12Mas of Aug 2024 | — | 634.7K | — |
| Formela Jean FrancoisDirector, 10% owner · 2 transactions | — | 1.58Mas of Oct 2012 | 317.4K | — | 140.0K |
| Atlas Venture Fund VII L P10% owner · 1 transaction | — | 1.34Mas of Mar 2010 | — | — | 140.0K |
| Klein Lawrence OttoChief Executive Officer, Director · 3 transactions | — | 925.6K | 76.7K | — | 3.5K |
| Lowe David GeorgeDirector · 10 transactions | — | 810.3Kas of Jul 2009 | — | — | 405.6K |
| Grais Linda SDirector · 2 transactions | — | 679.1Kas of Mar 2010 | — | — | 210.8K |
| Boulder Ventures IV Annex LP +7 co-filers10% owner · 4 transactions | — | 676.5Kas of Apr 2009 | — | — | — |
| Skyline Venture Partners Qualified Purchaser Fund IV L PFormer 10% owner · 7 transactions | — | 335.4Kas of Jun 2009 | — | — | 199.8K |
| Sandler Laura LeeChief Operating Officer · 17 transactions | — | 236.4K | 47.5K | — | 24.2K |
| Zabriskie John LDirector · 1 transaction | — | 156.1Kas of Oct 2012 | 127.0K | — | — |
| Wheeler Patrick MChief Financial Officer · 3 transactions | — | 101.5Kas of Sep 2014 | 109.2K | — | 8.2K |
| Edwards Larry ToddChief Commercial Officer · 1 transaction | — | 100.0K | 100.0K | — | — |
| Ozeroff Christopher DavidS.V.P., General Counsel · 14 transactions | — | 51.0Kas of Dec 2021 | 200.8K | 50.0K | 4.0K |
| Conway Robert EReporting owner · 8 transactions | — | 50.0Kas of Jan 2024 | — | 83.1K | — |
| Keuer Thomas AChief Operating Officer · 12 transactions | — | 40.7Kas of Dec 2022 | 65.3K | — | 5.0K |
| Dekker C. JeffreyChief Financial Officer · 1 transaction | — | 40.0Kas of Dec 2022 | 40.0K | — | — |
| Goncalves JoanaChief Medical Officer · 37 transactions | — | 39.0K | 81.5K | — | 50.6K |
| Dambkowski CarlDirector · 9 transactions | — | 38.7K | 62.3K | — | 140.0K |
| Perry Mark LDirector · 5 transactions | — | 35.8Kas of Sep 2006 | 65.8K | — | — |
| Quinlan Paul TGeneral Counsel · 3 transactions | — | 31.0K | 32.5K | — | 1.5K |
| Levy Michael DExecutive Vice President · 6 transactions | — | 20.8Kas of Aug 2007 | — | — | — |
| Titus GaryChief Acct.Officer · 16 transactions | — | 16.6Kas of Aug 2006 | 75.8K | — | 75.8K |
| Agarwal ArjunSenior Vice President, Finance · 16 transactions | — | 15.3K | 34.8K | — | 22.1K |
| Falberg Kathryn ECFO and COO · 11 transactions | — | 12.7Kas of Jun 2009 | — | — | 21.0K |
| Bristow Michael RPres. & Chief Executive Offic, Director · 16 transactions | — | 8.5Kas of Dec 2021 | 1.07M | 1.07M | 26.0K |
| Love Ted WDirector · 8 transactions | — | 3.6Kas of May 2008 | — | 29.0K | — |
| Bendekgey E LeeCFO and Treasurer · 13 transactions | — | 1.5Kas of Nov 2008 | — | — | — |
| Mitchell Daniel JDirector · 1 transaction | — | 611as of Jan 2024 | — | 11.0K | — |
| Wolff Henry WardSr. VP Finance and CFO · 1 transaction | — | 229as of Nov 2006 | — | — | — |
| Koh Bong Y +7 co-filers10% owner · 2 transactions | — | 0as of Feb 2018 | — | — | 1.54M |
| Barris Peter J10% owner · 1 transaction | — | 0as of Feb 2018 | — | — | 1.46M |
| Baskett Forest10% owner · 1 transaction | — | 0as of Feb 2018 | — | — | 1.46M |
| Florence Anthony A. Jr.10% owner · 1 transaction | — | 0as of Feb 2018 | — | — | 1.46M |
| Growth Equity Opportunities IV, LLC +3 co-filers10% owner · 1 transaction | — | 0as of Feb 2018 | — | — | 1.46M |
| Makower Joshua10% owner · 1 transaction | — | 0as of Feb 2018 | — | — | 1.46M |
| Mott David M10% owner · 1 transaction | — | 0as of Feb 2018 | — | — | 1.46M |
| Sandell Scott D10% owner · 1 transaction | — | 0as of Feb 2018 | — | — | 1.46M |
| Sakoda Jon10% owner · 1 transaction | — | 0as of Feb 2018 | — | — | 1.46M |
| Sonsini Peter W.10% owner · 1 transaction | — | 0as of Feb 2018 | — | — | 1.46M |
| Viswanathan Ravi10% owner · 1 transaction | — | 0as of Feb 2018 | — | — | 1.46M |
| Sobel Burton EDirector · 11 transactions | — | 0as of Nov 2006 | 25.0K | — | 37.5K |
| Selby Brian L.VP, Finance · 10 transactions | — | 0as of Apr 2018 | 23.4K | — | 5.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -14.81M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.